Modification and Regulation during IFNβ Expression
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v4i1.1128
Abstract
IFNβ is encoded by a single-copy gene without introns. It is only expressed when the body needs or is stimulated, and causes a series of response mechanisms. At present, the transcriptional regulation of IFNβ is still a research hotspot, and the expression of IFNβ is regulated by the corresponding transcriptional regulators transmitted and activated by different signaling pathways. With the further exploration in recent years, a large number of new regulatory mechanisms have been discovered, especially the research on the modification of the entire regulatory process, but there is currently a lack of a comprehensive overview of this complex modification network. This review focuses on this, and provides a comprehensive and systematic overview of the modification and regulation of IFNβ expression, and integrates the latest research results so that readers can have a comprehensive understanding of the regulation and modification of IFNβ in this review.
Keywords
IFNβ, transcriptional regulator, signaling pathway, epigenetic modification, transcriptional regulation
Full Text
PDF - Viewed/Downloaded: 0 TimesIndexation
Download Index RecordReferences
[1]Meyts I, Casanova JL. Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway. Eur J Immunol 2021; 51(5):1039-1061.
[2]Sugrue JA, Bourke NM, O'Farrelly C. Type I Interferon and the Spectrum of Susceptibility to Viral Infection and Autoimmune Disease: A Shared Genomic Signature. Front Immunol 2021; 12:757249.
[3]Gallucci S, Meka S, Gamero AM. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine 2021; 146:155633.
[4]Chen Y, Lin J, Zhao Y, Ma X, Yi H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B 2021; 22(8):609-632.
[5]Zhang Y, Chen S, Jin Y, Ji W, Zhang W, Duan G. An Update on Innate Immune Responses during SARS-CoV-2 Infection. Viruses 2021; 13(10).
[6]Sanford SAI, McEwan WA. Type-I Interferons in Alzheimer's Disease and Other Tauopathies. Front Cell Neurosci 2022; 16:949340.
[7]de Mattos K, Viger RS, Tremblay JJ. Transcription Factors in the Regulation of Leydig Cell Gene Expression and Function. Front Endocrinol (Lausanne) 2022; 13:881309.
[8]Houliston RS, Lemak A, Iqbal A, Ivanochko D, Duan S, Kaustov L, et al. Conformational dynamics of the TTD-PHD histone reader module of the UHRF1 epigenetic regulator reveals multiple histone-binding states, allosteric regulation, and druggability. J Biol Chem 2017; 292(51):20947-20959.
[9]Tan Y, Liu Q, Li Z, Yang S, Cui L. Epigenetics-mediated pathological alternations and their potential in antiphospholipid syndrome diagnosis and therapy. Autoimmun Rev 2022; 21(8):103130.
[10]Gao ZJ, Li WP, Mao XT, Huang T, Wang HL, Li YN, et al. Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity. J Exp Med 2021; 218(3).
[11]Wang J, Hua H, Wang F, Yang S, Zhou Q, Wu X, et al. Arginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway. Mol Immunol 2021; 139:202-210.
[12]Tong J, Zhang W, Chen Y, Yuan Q, Qin NN, Qu G. The Emerging Role of RNA Modifications in the Regulation of Antiviral Innate Immunity. Front Microbiol 2022; 13:845625.
[13]Rubio RM, Depledge DP, Bianco C, Thompson L, Mohr I. RNA m(6) A modification enzymes shape innate responses to DNA by regulating interferon beta. Genes Dev 2018; 32(23-24):1472-1484.
[14]McFadden MJ, Horner SM. N(6)-Methyladenosine Regulates Host Responses to Viral Infection. Trends Biochem Sci 2021; 46(5):366-377.
[15]Chen J, Wei X, Wang X, Liu T, Zhao Y, Chen L, et al. TBK1-METTL3 axis facilitates antiviral immunity. Cell Rep 2022; 38(7):110373.
[16]Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. J Autoimmun 2017; 83:1-11.
[17]Muntyanu A, Le M, Ridha Z, O'Brien E, Litvinov IV, Lefrancois P, et al. Novel role of long non-coding RNAs in autoimmune cutaneous disease. J Cell Commun Signal 2021.
[18]Chen X, Cheng Q, Wu H, Du Y. Long non-coding RNAs in systemic lupus erythematosus: New insights into disease pathogenesis and diagnosis. Scand J Immunol 2022; 95(6):e13167.
[19]Suarez B, Prats-Mari L, Unfried JP, Fortes P. LncRNAs in the Type I Interferon Antiviral Response. Int J Mol Sci 2020; 21(17).
[20]Gao Y, Zhang N, Zeng Z, Wu Q, Jiang X, Li S, et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. Clin Transl Med 2022; 12(4):e792.
[21]Mo L, Zeng Z, Deng R, Li Z, Sun J, Hu N, et al. Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-beta signaling by targeting adaptor protein TRAF6. Arch Virol 2021; 166(3):789-799.
[22]Ghafouri-Fard S, Poornajaf Y, Dashti F, Hussen BM, Taheri M, Jamali E. Interaction Between Non-Coding RNAs and Interferons: With an Especial Focus on Type I Interferons. Front Immunol 2022; 13:877243.
[23]Liu W, Wang Z, Liu L, Yang Z, Liu S, Ma Z, et al. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc Natl Acad Sci U S A 2020; 117(38):23695-23706.
[24]Gao F, Tan Y, Luo H. MALAT1 is involved in type I IFNs-mediated systemic lupus erythematosus by up-regulating OAS2, OAS3, and OASL. Braz J Med Biol Res 2020; 53(5):e9292.
[25]Forster SC, Tate MD, Hertzog PJ. MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response. Front Immunol 2015; 6:334.
[26]Rah B, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M, et al. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Front Pharmacol 2022; 13:821344.
[27]Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, et al. The JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med 2022; 26(7):2049-2062.
[28]Armache A, Yang S, Martinez de Peace A, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature 2020; 583(7818):852–8
[29]Liu Z, Yang L, Sun Y, Xie X, Huang J. ASF1a enhances antiviral immune response by associating with CBP to mediate acetylation of H3K56 at the Ifnb promoter. Mol Immunol 2016; 78:57-64.
[30]Gao W, Wang L, Ju X, Zhao S, Li Z, Su M, et al. The Deubiquitinase USP29 Promotes SARS-CoV-2 Virulence by Preventing Proteasome Degradation of ORF9b. mBio 2022; 13(3):e0130022.
[31]Wang L, Ning S. TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense. Viruses 2021; 13(2).
[32]Zhang XZ, Li FH, Wang XJ. Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion. Front Microbiol 2021; 12:794882.
[33]El Motiam A, Vidal S, Seoane R, Bouzaher YH, Gonzalez-Santamaria J, Rivas C. SUMO and Cytoplasmic RNA Viruses: From Enemies to Best Friends. Adv Exp Med Biol 2020; 1233:263-277.
[34]Imbert F, Leavitt G, Langford D. SUMOylation and Viral Infections of the Brain. Pathogens 2022; 11(7).
[35]El-Asmi F, McManus FP, Thibault P, Chelbi-Alix MK. Interferon, restriction factors and SUMO pathways. Cytokine Growth Factor Rev 2020; 55:37-47.
[36]Chelbi-Alix MK, Thibault P. Crosstalk Between SUMO and Ubiquitin-Like Proteins: Implication for Antiviral Defense. Front Cell Dev Biol 2021; 9:671067.
[37]Chiang C, Liu G, Gack MU. Viral Evasion of RIG-I-Like Receptor-Mediated Immunity through Dysregulation of Ubiquitination and ISGylation. Viruses 2021; 13(2).
[38]Hernandez-Diaz T, Valiente-Echeverria F, Soto-Rifo R. RNA Helicase DDX3: A Double-Edged Sword for Viral Replication and Immune Signaling. Microorganisms 2021; 9(6).
[39]Lin WJ, Zheng X, Lin CC, Tsao J, Zhu X, Cody JJ, et al. Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection. Mol Cell Biol 2011; 31(16):3196-3207.
[2]Sugrue JA, Bourke NM, O'Farrelly C. Type I Interferon and the Spectrum of Susceptibility to Viral Infection and Autoimmune Disease: A Shared Genomic Signature. Front Immunol 2021; 12:757249.
[3]Gallucci S, Meka S, Gamero AM. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine 2021; 146:155633.
[4]Chen Y, Lin J, Zhao Y, Ma X, Yi H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B 2021; 22(8):609-632.
[5]Zhang Y, Chen S, Jin Y, Ji W, Zhang W, Duan G. An Update on Innate Immune Responses during SARS-CoV-2 Infection. Viruses 2021; 13(10).
[6]Sanford SAI, McEwan WA. Type-I Interferons in Alzheimer's Disease and Other Tauopathies. Front Cell Neurosci 2022; 16:949340.
[7]de Mattos K, Viger RS, Tremblay JJ. Transcription Factors in the Regulation of Leydig Cell Gene Expression and Function. Front Endocrinol (Lausanne) 2022; 13:881309.
[8]Houliston RS, Lemak A, Iqbal A, Ivanochko D, Duan S, Kaustov L, et al. Conformational dynamics of the TTD-PHD histone reader module of the UHRF1 epigenetic regulator reveals multiple histone-binding states, allosteric regulation, and druggability. J Biol Chem 2017; 292(51):20947-20959.
[9]Tan Y, Liu Q, Li Z, Yang S, Cui L. Epigenetics-mediated pathological alternations and their potential in antiphospholipid syndrome diagnosis and therapy. Autoimmun Rev 2022; 21(8):103130.
[10]Gao ZJ, Li WP, Mao XT, Huang T, Wang HL, Li YN, et al. Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity. J Exp Med 2021; 218(3).
[11]Wang J, Hua H, Wang F, Yang S, Zhou Q, Wu X, et al. Arginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway. Mol Immunol 2021; 139:202-210.
[12]Tong J, Zhang W, Chen Y, Yuan Q, Qin NN, Qu G. The Emerging Role of RNA Modifications in the Regulation of Antiviral Innate Immunity. Front Microbiol 2022; 13:845625.
[13]Rubio RM, Depledge DP, Bianco C, Thompson L, Mohr I. RNA m(6) A modification enzymes shape innate responses to DNA by regulating interferon beta. Genes Dev 2018; 32(23-24):1472-1484.
[14]McFadden MJ, Horner SM. N(6)-Methyladenosine Regulates Host Responses to Viral Infection. Trends Biochem Sci 2021; 46(5):366-377.
[15]Chen J, Wei X, Wang X, Liu T, Zhao Y, Chen L, et al. TBK1-METTL3 axis facilitates antiviral immunity. Cell Rep 2022; 38(7):110373.
[16]Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review. J Autoimmun 2017; 83:1-11.
[17]Muntyanu A, Le M, Ridha Z, O'Brien E, Litvinov IV, Lefrancois P, et al. Novel role of long non-coding RNAs in autoimmune cutaneous disease. J Cell Commun Signal 2021.
[18]Chen X, Cheng Q, Wu H, Du Y. Long non-coding RNAs in systemic lupus erythematosus: New insights into disease pathogenesis and diagnosis. Scand J Immunol 2022; 95(6):e13167.
[19]Suarez B, Prats-Mari L, Unfried JP, Fortes P. LncRNAs in the Type I Interferon Antiviral Response. Int J Mol Sci 2020; 21(17).
[20]Gao Y, Zhang N, Zeng Z, Wu Q, Jiang X, Li S, et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. Clin Transl Med 2022; 12(4):e792.
[21]Mo L, Zeng Z, Deng R, Li Z, Sun J, Hu N, et al. Hepatitis A virus-induced hsa-miR-146a-5p attenuates IFN-beta signaling by targeting adaptor protein TRAF6. Arch Virol 2021; 166(3):789-799.
[22]Ghafouri-Fard S, Poornajaf Y, Dashti F, Hussen BM, Taheri M, Jamali E. Interaction Between Non-Coding RNAs and Interferons: With an Especial Focus on Type I Interferons. Front Immunol 2022; 13:877243.
[23]Liu W, Wang Z, Liu L, Yang Z, Liu S, Ma Z, et al. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc Natl Acad Sci U S A 2020; 117(38):23695-23706.
[24]Gao F, Tan Y, Luo H. MALAT1 is involved in type I IFNs-mediated systemic lupus erythematosus by up-regulating OAS2, OAS3, and OASL. Braz J Med Biol Res 2020; 53(5):e9292.
[25]Forster SC, Tate MD, Hertzog PJ. MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response. Front Immunol 2015; 6:334.
[26]Rah B, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M, et al. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Front Pharmacol 2022; 13:821344.
[27]Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, et al. The JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med 2022; 26(7):2049-2062.
[28]Armache A, Yang S, Martinez de Peace A, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature 2020; 583(7818):852–8
[29]Liu Z, Yang L, Sun Y, Xie X, Huang J. ASF1a enhances antiviral immune response by associating with CBP to mediate acetylation of H3K56 at the Ifnb promoter. Mol Immunol 2016; 78:57-64.
[30]Gao W, Wang L, Ju X, Zhao S, Li Z, Su M, et al. The Deubiquitinase USP29 Promotes SARS-CoV-2 Virulence by Preventing Proteasome Degradation of ORF9b. mBio 2022; 13(3):e0130022.
[31]Wang L, Ning S. TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense. Viruses 2021; 13(2).
[32]Zhang XZ, Li FH, Wang XJ. Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion. Front Microbiol 2021; 12:794882.
[33]El Motiam A, Vidal S, Seoane R, Bouzaher YH, Gonzalez-Santamaria J, Rivas C. SUMO and Cytoplasmic RNA Viruses: From Enemies to Best Friends. Adv Exp Med Biol 2020; 1233:263-277.
[34]Imbert F, Leavitt G, Langford D. SUMOylation and Viral Infections of the Brain. Pathogens 2022; 11(7).
[35]El-Asmi F, McManus FP, Thibault P, Chelbi-Alix MK. Interferon, restriction factors and SUMO pathways. Cytokine Growth Factor Rev 2020; 55:37-47.
[36]Chelbi-Alix MK, Thibault P. Crosstalk Between SUMO and Ubiquitin-Like Proteins: Implication for Antiviral Defense. Front Cell Dev Biol 2021; 9:671067.
[37]Chiang C, Liu G, Gack MU. Viral Evasion of RIG-I-Like Receptor-Mediated Immunity through Dysregulation of Ubiquitination and ISGylation. Viruses 2021; 13(2).
[38]Hernandez-Diaz T, Valiente-Echeverria F, Soto-Rifo R. RNA Helicase DDX3: A Double-Edged Sword for Viral Replication and Immune Signaling. Microorganisms 2021; 9(6).
[39]Lin WJ, Zheng X, Lin CC, Tsao J, Zhu X, Cody JJ, et al. Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection. Mol Cell Biol 2011; 31(16):3196-3207.
Copyright © 2023 Jiqiang Fan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License